Developer docs
API playgroundTry for free, no card

Search company profiles

Humboldt Fund

Full company profile

uuid00093cq

Namestring
Humboldt Fund
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Humboldt Fund is a privately-held investment firm headquartered in New York, United States. Per available firmographic data, the firm focuses on investing in companies operating within the "bio revolution" sector, indicating a thesis-driven mandate oriented toward biology-adjacent and life-sciences ventures. The firm operates with a small team of 1-10 employees, consistent with an emerging or early-stage venture capital structure. Benjamin Quiroga is identified as the founder and co-founder.

The firm's public footprint is minimal. Its website (humboldtfund.com) currently displays only the company name, the word "Humboldt," and a logo, with no disclosed portfolio companies, fund size, investment stage focus, sector thesis detail, team page, or contact information beyond the founder reference. No app, API, integrations, or technology products are associated with the firm in the source data. The "doing business as" name in the source material is listed simply as "Humboldt," with no sub-brands or prior names disclosed.

No revenue, AUM, fund vintage, capital commitments, LP base, partnerships, awards, regulatory actions, or M&A activity are documented in the available data. There are no disclosed funding rounds, parent entities, subsidiaries, or office locations beyond the New York headquarters. The combination of a 1-10 employee headcount, a logo-only website, and the absence of any disclosed portfolio or fund vehicle in the source material indicates either a fund in early formation, a recently launched vehicle that has not yet publicly deployed capital, or a deliberately low-profile operation. Any further characterization of fund mechanics, investment cadence, or capital structure would exceed what the source data supports.

Short descriptiontext

Humboldt Fund is a New York-based private investment firm with 1-10 employees that targets bio revolution companies. Founded by Benjamin Quiroga, the firm maintains a minimal public footprint with no disclosed portfolio, fund size, or operational details beyond its name, logo, and stated sector focus.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital investing, bio revolution investing, life sciences venture capital, biotech early-stage investment, thematic equity investing
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
NAICS code2 codes
  • Other Investment Pools and Funds5259
  • Funds, Trusts, and Other Financial Vehicles525
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Venture Capital / Bio-focused Investment
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Humboldt Fund is an investment firm that deploys capital into bio revolution companies. Its core offering is venture/private investment exposure to biology-driven businesses, with the firm operating as a small, founder-led vehicle headquartered in New York.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data provides only minimal information about Humboldt Fund - a homepage displaying the company name and logo. No product or service details are available in the provided content.

Product and service1 record
1Humboldt Fund (Investment Vehicle)
CategoryVenture Capital / Bio-focused Investment
Description

Humboldt Fund is an investment vehicle that deploys capital into bio revolution companies. It is designed for investors seeking venture capital exposure to biology-driven businesses, and for bio revolution companies seeking venture capital funding.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Y Combinator
TypeEmerging player
Description

YC funds a growing share of bio and synbio startups through its standard accelerator and dedicated bio track, providing comparable early-stage exposure to bio revolution companies though via an accelerator model rather than a thesis fund.

TypeDirect peer
Description

ARCH is a leading early-stage venture firm focused on biotech, advanced materials, and deep tech — directly comparable to Humboldt's bio revolution mandate, though operating at significantly greater scale and with longer track record.

TypeDirect peer
Description

Flagship originates and funds bio-platform companies (e.g., Moderna), making it the closest thematic peer to a fund investing in bio revolution companies — both target the same convergence of biology and technology.

TypeDirect peer
Description

Lux Capital invests at the intersection of science, technology, and biology, with a portfolio spanning synbio, neurotech, and frontier bio — making it a strong thematic peer to a bio-revolution-focused fund.

TypeDirect peer
Description

Khosla invests aggressively across bio, synbio, health, and deep tech from seed onward — a directly comparable thesis-driven early-stage investor in bio revolution companies.

TypeDirect peer
Description

Breakout Ventures funds early-stage companies at the intersection of biology and technology, making it a directly comparable early-stage bio-focused peer.

TypeDirect peer
Description

Civilization Ventures invests in health, biotech, and technology platforms — a directly comparable emerging bio-focused venture firm at similar early stage.

TypeDirect peer
Description

Section32 is a venture fund specifically focused on health, biotech, and digital health — directly comparable to Humboldt's bio-thesis focus area.

TypeDirect peer
Description

Digitalis Ventures invests at the intersection of biology, engineering, and computation — directly comparable thematic peer for a fund targeting the bio revolution.

TypeBroad incumbent
Description

a16z operates a dedicated Bio + Health fund investing across bio, digital health, and therapeutics — a broad incumbent with overlapping bio-thesis exposure though part of a much larger multi-stage platform.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment26 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Humboldt Fund

Venture Capital / Bio-focused Investmenthumboldtfund.com

Humboldt Fund is a New York-based private investment firm with 1-10 employees that targets bio revolution companies. Founded by Benjamin Quiroga, the firm maintains a minimal public footprint with no disclosed portfolio, fund size, or operational details beyond its name, logo, and stated sector focus.

What Humboldt Fund does

Humboldt Fund is a privately-held investment firm headquartered in New York, United States. Per available firmographic data, the firm focuses on investing in companies operating within the "bio revolution" sector, indicating a thesis-driven mandate oriented toward biology-adjacent and life-sciences ventures. The firm operates with a small team of 1-10 employees, consistent with an emerging or early-stage venture capital structure. Benjamin Quiroga is identified as the founder and co-founder.

The firm's public footprint is minimal. Its website (humboldtfund.com) currently displays only the company name, the word "Humboldt," and a logo, with no disclosed portfolio companies, fund size, investment stage focus, sector thesis detail, team page, or contact information beyond the founder reference. No app, API, integrations, or technology products are associated with the firm in the source data. The "doing business as" name in the source material is listed simply as "Humboldt," with no sub-brands or prior names disclosed.

No revenue, AUM, fund vintage, capital commitments, LP base, partnerships, awards, regulatory actions, or M&A activity are documented in the available data. There are no disclosed funding rounds, parent entities, subsidiaries, or office locations beyond the New York headquarters. The combination of a 1-10 employee headcount, a logo-only website, and the absence of any disclosed portfolio or fund vehicle in the source material indicates either a fund in early formation, a recently launched vehicle that has not yet publicly deployed capital, or a deliberately low-profile operation. Any further characterization of fund mechanics, investment cadence, or capital structure would exceed what the source data supports.

Humboldt Fund firmographics

Firmographics
Name
Humboldt Fund
Website
https://humboldtfund.com
Company type
Private
Headcount range
1–10 employees
Short description
Humboldt Fund is a New York-based private investment firm with 1-10 employees that targets bio revolution companies. Founded by Benjamin Quiroga, the firm maintains a minimal public footprint with no disclosed portfolio, fund size, or operational details beyond its name, logo, and stated sector focus.
Ownership category
akta.pro rank

Humboldt Fund industry classification

Industry
Product category
Venture Capital / Bio-focused Investment
NAICS
Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

  • Venture capital investing
  • Bio revolution investing
  • Life sciences venture capital
  • Biotech early-stage investment
  • Thematic equity investing

Where Humboldt Fund is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Humboldt Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Humboldt Fund product offering

Product offering

Core offering

Humboldt Fund is an investment firm that deploys capital into bio revolution companies. Its core offering is venture/private investment exposure to biology-driven businesses, with the firm operating as a small, founder-led vehicle headquartered in New York.

Product overview

The source data provides only minimal information about Humboldt Fund - a homepage displaying the company name and logo. No product or service details are available in the provided content.

Differentiator

Problem solved

Functional benefit

Products and services

  • Humboldt Fund (Investment Vehicle) Humboldt Fund is an investment vehicle that deploys capital into bio revolution companies. It is designed for investors seeking venture capital exposure to biology-driven businesses, and for bio revolution companies seeking venture capital funding.

Companies that use Humboldt Fund

Customer profile

Ideal customer profiles1 record

Humboldt Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Humboldt Fund partnerships and signals

Strategic signal

Recent moves2 records

Humboldt Fund competitors and assessment

Company assessment

Emerging players

  • Y Combinator: YC funds a growing share of bio and synbio startups through its standard accelerator and dedicated bio track, providing comparable early-stage exposure to bio revolution companies though via an accelerator model rather than a thesis fund.

Direct peers

  • ARCH Venture Partners: ARCH is a leading early-stage venture firm focused on biotech, advanced materials, and deep tech — directly comparable to Humboldt's bio revolution mandate, though operating at significantly greater scale and with longer track record.
  • Flagship Pioneering: Flagship originates and funds bio-platform companies (e.g., Moderna), making it the closest thematic peer to a fund investing in bio revolution companies — both target the same convergence of biology and technology.
  • Lux Capital: Lux Capital invests at the intersection of science, technology, and biology, with a portfolio spanning synbio, neurotech, and frontier bio — making it a strong thematic peer to a bio-revolution-focused fund.
  • Khosla Ventures: Khosla invests aggressively across bio, synbio, health, and deep tech from seed onward — a directly comparable thesis-driven early-stage investor in bio revolution companies.
  • Breakout Ventures: Breakout Ventures funds early-stage companies at the intersection of biology and technology, making it a directly comparable early-stage bio-focused peer.
  • Civilization Ventures: Civilization Ventures invests in health, biotech, and technology platforms — a directly comparable emerging bio-focused venture firm at similar early stage.
  • Section32: Section32 is a venture fund specifically focused on health, biotech, and digital health — directly comparable to Humboldt's bio-thesis focus area.
  • Digitalis Ventures: Digitalis Ventures invests at the intersection of biology, engineering, and computation — directly comparable thematic peer for a fund targeting the bio revolution.

Broad incumbents

  • Andreessen Horowitz (a16z Bio Fund): a16z operates a dedicated Bio + Health fund investing across bio, digital health, and therapeutics — a broad incumbent with overlapping bio-thesis exposure though part of a much larger multi-stage platform.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Humboldt Fund social profiles

Digital presence

Humboldt Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Humboldt Fund leadership team

Management profile

Number of profiles

Profiles1 record

Humboldt Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Humboldt Fund M&A and investment

M&A and investment

M&A

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humboldt Fund

What does Humboldt Fund do?

Humboldt Fund is an investment firm that deploys capital into bio revolution companies. Its core offering is venture/private investment exposure to biology-driven businesses, with the firm operating as a small, founder-led vehicle headquartered in New York.

When was Humboldt Fund founded?

Humboldt Fund was founded in -1. It employs 1 to 10 people.

Where is Humboldt Fund based?

Humboldt Fund is headquartered in New York, United States, in the North America region.

Who are Humboldt Fund's main competitors?

Y Combinator is listed as an emerging player. Direct peers are ARCH Venture Partners, Flagship Pioneering, Lux Capital, Khosla Ventures, Breakout Ventures, Civilization Ventures, Section32 and Digitalis Ventures. Andreessen Horowitz (a16z Bio Fund) is listed as a broad incumbent.

Does Humboldt Fund have an API?

No public API is recorded for Humboldt Fund.

What industry is Humboldt Fund in?

Humboldt Fund's product category is Venture Capital / Bio-focused Investment. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tracxn2026 Funding Rounds & List of InvestorsCellino has raised multiple funding rounds, including a Series A in September 2024 and earlier seed rounds in 2017-2021. The rounds show increasing post-money valuations, with the latest at $9,554,114. Lead investors include Felicis Ventures and Humboldt Fund.Tracxn2025 Company Profile, Team & FundingDebut, a provider of enzymes for biotherapeutic creation, has raised a total of $126 million in funding across eight rounds. Its latest Series B round of $20 million was completed on August 26, 2025, with participation from investors including Humboldt Fund and Cultivian Sandbox.163Breakthrough in stem cell therapy key bottleneck! Bayer leads, new company completes $80 million Series A financingCellino Biotech announced the completion of an $80 million Series A financing round led by Leaps by Bayer, along with 8VC and Humboldt Fund. The funds will be used to enhance Cellino's capabilities in automating the manufacturing of cell-based therapies. This innovative approach aims to significantly reduce production costs and increase patient access to these treatments.ForbesThis Stem Cell Manufacturing Startup Just Raised An $80 Million War Chest To Revolutionize MedicineCellino Biotech raised $80 million in Series A financing led by Leaps by Bayer, with participation from 8VC, Humboldt Fund, and others. The company aims to build the first autonomous human cell foundry in 2025 to automate stem cell manufacturing. The technology uses AI and laser technology to process patient samples in parallel.TechCrunchStartup Battlefield winner Cellino grabs $80M Series ACellino Bio, a biotech startup that won TechCrunch Disrupt 2021's Startup Battlefield, has raised an $80 million Series A round led by Leaps by Bayer, 8VC, and Humboldt Fund, with participation from Felicis Ventures, The Engine, and Khosla Ventures, bringing total funding to $96 million. The company is developing an autonomous, laser-based manufacturing platform to scale production of induced pluripotent stem cells for regenerative medicine, addressing a critical bottleneck in the field. Cellino is also collaborating with the National Eye Institute on a first-of-its-kind clinical trial to transplant personalized iPSCs into patient retinas to treat age-related macular degeneration, with the goal of building a fully autonomous human cell foundry by 2025.Diario FinancieroFirma de venture capital ligada al fundador de Mercado Libre pone sus fichas en biotech chilena | Diario FinancieroKaszek Ventures, led by Mercado Libre co-founder Hernán Kazah, closed a capital increase with Chilean biotech Phage Lab for nearly $30 million. The startup develops bacteriophages for animals, including a bovine product with Bayer and a salmonella control for poultry. Humboldt Fund and Kaszek will co-lead the round, aiming for a unicorn exit.Business Wire BlogMetagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt FundMetagenomi, a gene editing company, closed a $65 million Series A financing round led by Leaps by Bayer and Humboldt Fund. The company emerged from stealth mode and will use the funds to expand its gene editing systems and advance preclinical validation. The round also includes Sozo Ventures, Agent Capital, InCube Ventures, and HOF Capital.Trust & Safety PoliciesFinch Closes $90 Million Series D to Advance C. Difficile Infection ProductFinch Therapeutics closed a $90 million Series D financing, with new investors including Baupost Group and Humboldt Fund. The company will use the funds to advance its lead candidate CP101 for recurrent C. difficile infection through clinical development and regulatory submission, and to launch a Phase Ib trial of FIN-211 for autism spectrum disorder and CP101 for chronic hepatitis B.